Evidence map›Paper›PMID 35294546›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3).

Morihito Okada, Ken Kato, Byoung Chul Cho, Masanobu Takahashi, Chen-Yuan Lin, Keisho Chin, Shigenori Kadowaki, Myung-Ju Ahn, Yasuo Hamamoto, Yuichiro Doki and 9 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 6 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 6 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 17 institutions in 7 countries.

Morihito OkadaDepartment of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID 0000-0002-1589-9114
Ken KatoDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0002-1733-5072
Byoung Chul ChoDivision of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.ORCID 0000-0002-5562-270X
Masanobu TakahashiDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.ORCID 0000-0001-9306-7041
Chen-Yuan LinDepartment of Hematology and Oncology, China Medical University Hospital and School of Pharmacy, China Medical University, Taichung City, Taiwan.
Keisho ChinGastroenterological Chemotherapy Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Shigenori KadowakiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.ORCID 0000-0001-9923-5309
Myung-Ju AhnDepartment of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.ORCID 0000-0002-5740-9654
Yasuo HamamotoDepartment of Internal Medicine, Keio Cancer Center, School of Medicine, Keio University, Tokyo, Japan.ORCID 0000-0002-5737-122X
Yuichiro DokiDepartment of Surgery, Osaka University Hospital, Osaka, Japan.
Chueh-Chuan YenDivision of Clinical Research, Department of Medical Research and Division of Medical Oncology, Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital and National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan.
Yutaro KubotaDepartment of Oncology, Showa University Hospital, Tokyo, Japan.
Sung-Bae KimDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.ORCID 0000-0001-5588-8332
Chih-Hung HsuDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Eva HoltvedDepartment of Clinical Oncology, Odense University Hospital, Odense, Denmark.
Ioannis XynosOncology Clinical Development, Bristol-Myers Squibb, Princeton, New Jersey.
Yasuhiro MatsumuraOncology Clinical Development, Ono Pharmaceutical Co., Ltd., Osaka, Japan.ORCID 0000-0002-1451-8631
Akira TakazawaData Science, Ono Pharmaceutical Co., Ltd., Osaka, Japan.ORCID 0000-0002-4755-8007
Yuko KitagawaDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Keio University · JPOno Pharmaceutical (Japan) · JPAichi Cancer Center · JPBristol-Myers Squibb (Germany) · DEChina Medical University · TWHiroshima University · JPJapanese Foundation For Cancer Research · JPNational Cancer Centre Japan · JPNational Taiwan University Hospital · TWOdense University Hospital · DKOsaka University Hospital · JPSamsung Medical Center · KRShowa University Hospital · JPTaipei Veterans General Hospital · TWTohoku University Hospital · JPUniversity of Ulsan · KRYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLimited long-term data are available on immune checkpoint inhibitor use in patients with advanced esophageal squamous cell carcinoma (ESCC). We report 3-year follow-up data from our study of nivolumab versus chemotherapy (paclitaxel or docetaxel) in patients with previously treated ESCC. PATIENTS AND

methodsATTRACTION-3 was a randomized, multicenter, open-label, phase III trial. Overall survival (OS), time from randomization to death from any cause, was the primary endpoint. An exploratory subanalysis assessed OS according to the best overall response (BOR) with and without landmark at 4 months.

resultsOf the enrolled patients, 210 received nivolumab and 209 received chemotherapy. With a minimum follow-up of 36.0 months, OS was longer in the nivolumab versus the chemotherapy group (median, 10.9 vs. 8.5 months; HR, 0.79; P = 0.0264), with 3-year OS rates of 15.3% and 8.7%, respectively. The median OS was longer with nivolumab versus chemotherapy irrespective of the BOR (complete response/partial response: 19.9 vs. 15.4 months; stable disease: 17.4 vs. 8.8 months; and progressive disease: 7.6 vs. 4.2 months). Grade 3 or higher treatment-related adverse events were reported in 40 patients (19.1%) in the nivolumab group and 133 patients (63.9%) in the chemotherapy group.

conclusionsNivolumab as second-line therapy demonstrated clinically meaningful long-term improvement in OS compared with chemotherapy in previously treated patients with advanced ESCC. The OS was consistently improved in the nivolumab group compared with the chemotherapy group regardless of BOR. Nivolumab was well tolerated over the 3-year follow-up. See related commentary by Yoon et al., p. 3173.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaFollow-Up StudiesHumansNivolumabProgrammed Cell Death 1 ReceptorNivolumabProgrammed Cell Death 1 Receptor

Identifiers

PMID35294546
PMCPMC9662935
OpenAlexW4220750579

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.